Globus Medical stock has delivered a 60.1% gain over the past three years, yet the broader valuation checks still flag it as looking cheap rather than fully priced in. With margins in the spotlight after recent earnings coverage, investors are weighing whether the current share price properly reflects both the strengths and the pressures in the business. A 60.1% return over three years suggests the market has reassessed Globus Medical positively, but it does not yet rule out further...

PEG-driven GARP picks EnerSys, Globus Medical, DoubleVerify and Match Group pair discounted valuations with strong growth potential.

BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.

Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.

MMED's MiniMed Flex is now shipping in the U.S. with Abbott's 15-day Instinct sensor, pairing discreet app control with automated insulin delivery.

EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.

ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.

Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.

Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.

ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.

CI's growth and shareholder returns are weighed against rising costs, medical expenses and debt, keeping investors neutral for now.

Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.

Phibro Animal Health's Animal Health growth and global reach support its outlook, but Brazil's antimicrobial transition and trade risks cloud near-term prospects.

SNN launches the FLOW FLEXTEND COBLATION Wand, offering adjustable-angle access and precise tissue removal in complex joint procedures.

CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.

Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.

The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.

IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.

MD's stronger cash collections, favorable payer mix, acquisitions and telehybrid care support its growth prospects.

RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.

Globus Medical has seen its assessed fair value cut from US$107.42 to US$103.23, a modest 3.9% trim that reflects a cooler view on upside from current levels. Recent research has highlighted a split narrative, with some analysts pointing to earnings strength and integration progress, while others focus on softer growth expectations and a tighter trading range for price targets. As you read on, you will see how these differing views fit together and how to track the evolving story around...

Globus Medical (GMED) has been in focus after a recent upgrade to Zacks Rank #1, which came shortly after the company reaffirmed its 2026 revenue guidance and released its latest quarterly earnings. See our latest analysis for Globus Medical. Over the past year, Globus Medical has seen a 36.44% total shareholder return and a 10.96% 90 day share price return. This suggests momentum has been building again around the recent earnings update and reaffirmed 2026 guidance. If you are looking for...

Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.

ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.

Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.

BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.

Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.

Globus Medical (GMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GMED vs. ITGR: Which Stock Is the Better Value Option?

Globus Medical (NYSE:GMED) reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted

Globus Medical raises 2026 EPS guidance after Q2 margin gains and spine growth while holding sales guidance steady amid Nevro and Enabling Technologies risks.

Globus Medical Inc (GMED) delivers record Q2 EPS with 56% growth, while navigating Nevro stabilization and enabling tech transition.

While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Globus Medical (GMED) delivered earnings and revenue surprises of +19.64% and +0.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company Globus Medical (NYSE:GMED) announced better-than-expected revenue in Q2 CY2026, with sales up 5.9% year on year to $789.6 million. The company expects the full year’s revenue to be around $3.2 billion, close to analysts’ estimates. Its non-GAAP profit of $1.34 per share was 21.9% above analysts’ consensus estimates.

Globus Medical and Resmed enter the earnings season with growth drivers intact despite tariff, inflation and hospital spending pressures.

Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.

Globus Medical stock has delivered a strong 52.3% return over the past year, and the key issue now is whether that share price strength still lines up with what the valuation checks suggest about the company. Over the last 12 months Globus Medical has returned 52.3%, which puts the focus squarely on whether the current price already reflects the progress the business has made. Upcoming earnings on 6 August 2026 may help support the current valuation if revenue growth and profitability track...

In the world of robotic surgery, one company is both the undisputed leader and the most expensive name on the shelf, forcing investors to ask if operational brilliance is worth the high price of admission.

The robotic surgery leader's shares have pulled back, forcing investors to weigh a solid recovery record against new questions in its most important market.

GMED is gaining share in musculoskeletal solutions with strong implant and trauma growth, backed by a debt-free balance sheet despite cost and FX pressures.

At $353, Intuitive Surgical (ISRG) is being priced to deliver 14.1% revenue growth annually for the next 4 years simply to defend today's 42.1x multiple. That sits below the 21% the business is currently growing at, which is the unusual part. The multiple has already priced in a slowdown that has not yet appeared.

You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.

The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.

Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.